Atlas Trials

Relenvatinib in the Tatment of Recurrence of Hepatocellular Carcinoma After Liver Transplantation

Clinical trial NCT04237740 · UNKNOWN

Trial details

NCT number
NCT04237740
Sponsor
RenJi Hospital
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
Hepatocellular CarcinomaLiver Transplantation
Start date
2020-05-01
Primary completion
2022-01-01
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.